Total Payments
$975,186
2024 Payments
$457.30
Companies
35
Transactions
1,382
Medicare Patients
729
Medicare Billing
$134,080
Payment Breakdown by Category
Other$624,964 (64.1%)
Consulting$231,458 (23.7%)
Travel$78,453 (8.0%)
Food & Beverage$40,207 (4.1%)
Research$77.78 (0.0%)
Education$27.12 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $546,424 | 213 | 56.0% |
| Consulting Fee | $231,458 | 73 | 23.7% |
| Travel and Lodging | $78,453 | 201 | 8.0% |
| Food and Beverage | $40,207 | 859 | 4.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $35,400 | 10 | 3.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $25,910 | 9 | 2.7% |
| Honoraria | $17,230 | 13 | 1.8% |
| Unspecified | $77.78 | 1 | 0.0% |
| Education | $27.12 | 3 | 0.0% |
Payments by Type
General
$975,109
1,381 transactions
Research
$77.78
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $604,754 | 664 | $0 (2023) |
| ABBVIE INC. | $129,634 | 192 | $0 (2024) |
| INTERCEPT PHARMACEUTICALS, INC. | $73,787 | 92 | $0 (2023) |
| NESTLE HEALTHCARE NUTRITION INC. | $66,499 | 95 | $0 (2023) |
| Allergan, Inc. | $60,390 | 91 | $0 (2020) |
| Shionogi Inc | $9,205 | 16 | $0 (2020) |
| Bayer HealthCare Pharmaceuticals Inc. | $5,841 | 10 | $0 (2018) |
| Ironwood Pharmaceuticals, Inc | $5,795 | 10 | $0 (2022) |
| Synergy Pharmaceuticals Inc | $3,382 | 4 | $0 (2018) |
| Intra-Sana Laboratories | $3,374 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $457.30 | 21 | ABBVIE INC. ($85.81) |
| 2023 | $64,490 | 100 | NESTLE HEALTHCARE NUTRITION INC. ($23,032) |
| 2022 | $108,745 | 159 | ABBVIE INC. ($38,966) |
| 2021 | $95,404 | 165 | AbbVie Inc. ($39,376) |
| 2020 | $121,005 | 135 | Gilead Sciences, Inc. ($68,383) |
| 2019 | $210,675 | 276 | Gilead Sciences, Inc. ($152,728) |
| 2018 | $180,165 | 264 | Gilead Sciences, Inc. ($134,779) |
| 2017 | $194,245 | 262 | Gilead Sciences Inc ($182,464) |
All Payment Transactions
1,382 individual payment records from CMS Open Payments — Page 1 of 56
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 11/13/2024 | Braintree Laboratories, Inc. | SUTAB (Drug), SUFLAVE | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: GI COLON PREP | ||||||
| 11/08/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: VIROLOGY | ||||||
| 10/23/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $21.56 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/20/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| Category: Neuroscience | ||||||
| 09/13/2024 | Intra-Sana Laboratories | RELTONE 200 MG (Drug), GLYCATE, RELTONE 400 MG | Food and Beverage | In-kind items and services | $28.89 | General |
| Category: GALLSTONES | ||||||
| 09/11/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 08/21/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/10/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/26/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: VIROLOGY | ||||||
| 06/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Gastroenterology | ||||||
| 06/07/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $27.27 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: Gastroenterology | ||||||
| 05/03/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/24/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $25.00 | General |
| Category: Neuroscience | ||||||
| 03/15/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $22.73 | General |
| Category: THERAPY FOR CSID | ||||||
| 03/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| Category: Neuroscience | ||||||
| 02/28/2024 | ORPHALAN INC | CUVRIOR (Drug) | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: Hepatology | ||||||
| 01/10/2024 | VIVUS LLC | PANCREAZE (Drug) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/09/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: ENDOCRINOLOGY | ||||||
| 01/03/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: VIROLOGY | ||||||
| 12/06/2023 | QOL Medical, LLC | Sucraid (Drug) | Food and Beverage | Cash or cash equivalent | $22.73 | General |
| Category: THERAPY FOR CSID | ||||||
| 11/20/2023 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/08/2023 | VIVUS LLC | PANCREAZE (Drug) | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/09/2023 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: GASTROENTEROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Virally-Suppressed Subjects with Chronic Hepatitis B | Gilead Sciences, Inc. | $77.78 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 157 | 229 | $85,500 | $26,821 |
| 2022 | 8 | 221 | 285 | $153,120 | $40,975 |
| 2021 | 6 | 172 | 239 | $98,450 | $34,092 |
| 2020 | 7 | 179 | 251 | $118,060 | $32,192 |
Total Patients
729
Total Services
1,004
Medicare Billing
$134,080
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 52 | 99 | $14,850 | $7,404 | 49.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2023 | 21 | 21 | $31,500 | $7,224 | 22.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2023 | 14 | 14 | $25,200 | $5,750 | 22.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 22 | 35 | $6,300 | $3,704 | 58.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 14 | 14 | $2,100 | $1,232 | 58.7% |
| 76981 | Ultrasound scan of organ tissue for measuring elasticity | Office | 2023 | 13 | 13 | $3,900 | $1,229 | 31.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 21 | 33 | $1,650 | $277.20 | 16.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2022 | 26 | 26 | $46,800 | $11,542 | 24.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2022 | 24 | 25 | $37,500 | $9,067 | 24.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 44 | 69 | $12,420 | $7,407 | 59.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 49 | 76 | $11,400 | $6,305 | 55.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2022 | 23 | 23 | $36,800 | $2,202 | 6.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $3,500 | $2,199 | 62.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 21 | 21 | $3,150 | $2,162 | 68.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 20 | 31 | $1,550 | $91.89 | 5.9% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Office | 2021 | 27 | 27 | $40,500 | $10,255 | 25.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 50 | 85 | $15,300 | $9,921 | 64.8% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Office | 2021 | 15 | 16 | $28,800 | $7,154 | 24.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 36 | 53 | $7,950 | $4,259 | 53.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 15 | 15 | $3,750 | $2,374 | 63.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 29 | 43 | $2,150 | $129.00 | 6.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 58 | 107 | $19,260 | $10,100 | 52.4% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Office | 2020 | 25 | 26 | $39,000 | $9,249 | 23.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Office | 2020 | 14 | 14 | $25,200 | $5,937 | 23.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 18 | 18 | $4,500 | $2,413 | 53.6% |
About Dr. Calvin Pan, M.D
Dr. Calvin Pan, M.D is a Internal Medicine healthcare provider based in Flushing, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427062108.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Calvin Pan, M.D has received a total of $975,186 in payments from pharmaceutical and medical device companies, with $457.30 received in 2024. These payments were reported across 1,382 transactions from 35 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($546,424).
As a Medicare-enrolled provider, Pan has provided services to 729 Medicare beneficiaries, totaling 1,004 services with total Medicare billing of $134,080. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Gastroenterology
- Location Flushing, NY
- Active Since 07/28/2006
- Last Updated 04/19/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1427062108
Products in Payments
- Vemlidy (Drug) $233,644
- ZENPEP (Drug) $113,760
- OCALIVA (Drug) $73,630
- CREON (Drug) $70,691
- Epclusa (Drug) $49,996
- LINZESS (Drug) $27,125
- Mulpleta (Drug) $9,168
- Vosevi (Drug) $5,892
- Nexavar (Drug) $5,841
- Linzess (Drug) $5,776
- Mavyret (Drug) $3,826
- Trulance (Drug) $3,382
- RELTONE 200 MG (Drug) $3,348
- Viekira (Drug) $3,252
- Creon (Drug) $2,981
- VIBERZI (Drug) $2,441
- Mytesi (Drug) $1,619
- Lenvima (Drug) $1,350
- Kanuma (Drug) $960.26
- XIFAXAN (Drug) $615.06
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Flushing
Ari Bunim, Md, MD
Internal Medicine — Payments: $361,039
Internal Medicine $361,039
Glenn Turett, M.d, M.D
Internal Medicine — Payments: $231,558
Internal Medicine $231,558
Weining Liang, Md, MD
Internal Medicine — Payments: $180,077
Internal Medicine $180,077
Dr. Yong Yu, M.d, M.D
Internal Medicine — Payments: $144,144
Internal Medicine $144,144
Dr. John Sciales, M.d, M.D
Internal Medicine — Payments: $92,715
Internal Medicine $92,715
Dr. Pauline Lau, Md, MD
Internal Medicine — Payments: $88,898
Internal Medicine $88,898